

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 Jul 2026

Placental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical Trials

Protocol summary

Study aim

The main objective is to investigate the safety and efficacy of cell therapy in patients with ARDS caused by Coronavirus pneumonia as an open-labeled randomized clinical trial.

Design

A controlled randomized clinical trial phase 1-2

Settings and conduct

The study will be conducted at Masih Daneshvari Hospital and Shariati Hospital. Participants, outcome assessors, and analyzers are unaware of the allocation of study groups.

Participants/Inclusion and exclusion criteria

Patients aged 18 to 65 years are included in the study with a definitive diagnosis of COVID-19, which subsequently develops acute respiratory distress syndrome (mild or moderate). COVID-19 patients with severe underlying disease or allergies to the cell or its associated compounds are not included in the study.

Intervention groups

The patients allocated randomly to tree groups: 1) Intervention 1, Patients will receive three doses of MSCs. 2) Control, Patients will receive conventional therapy.

Main outcome variables

Safety ; Blood oxygen saturation; Decreased severity of pneumonia; Improvement of the acute respiratory syndrome

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200413047063N1**

Registration date: **2020-05-04, 1399/02/15**

Registration timing: **registered_while_recruiting**

Last update: **2020-05-04, 1399/02/15**

Update count: **0**

Registration date

2020-05-04, 1399/02/15

Registrant information

Name

Masoud Soleimani

Name of organization / entity

Tarbiat Modares University

Country

Iran (Islamic Republic of)

Phone

+98 21 8288 4508

Email address

soleimani.masoud@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-03-20, 1399/01/01

Expected recruitment end date

2020-06-09, 1399/03/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Placental Mesenchymal Stem cells for treatment of ARDS in Coronavirus infection, Phase 1 and 2 Clinical Trials

Public title

Placental Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 1-2 Clinical Trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Confirmation of 2019-nCoV infection by RT-PCR
Diagnosis of ARDS according to the Berlin definition of ARDS Requiring supplemental oxygen, PaO₂/oxygen absorption concentration (FiO₂) ≤ 300MMHG Pulmonary imaging shows that the focused progress > 50% in 24-48 hours Mild to Moderate 2019-nCoV pneumonia/ stay in the ICU <48 hours SOFA score between 2-3 point
Pneumonia that is judged by chest radiograph or CT

Exclusion criteria:

Severe allergies or allergies after 1st injection to stem cell preparations and their components Patients with a malignant tumor, other serious systemic diseases, and psychosis Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus Patients with previous history of pulmonary embolism Liver or kidney SOFA score of more than 3 points; combined with other organ failure (need organ support), Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) < 30) Pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or bacterial pneumonia Continuous use of immunosuppressive agents or organ transplants in the past 6 months In vitro life support (ECMO, ECCO2R, RRT) Pregnant or lactating women Uncontrolled underlying disease Be thought by researchers to be inappropriate to participate in this clinical study (Expected deaths within 48 hours, uncontrolled infections)

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

1-2

Groups that have been masked

No information

Sample size

Target sample size: **20**

Randomization (investigator's opinion)

Randomized

Randomization description

Participants were randomly divided into two equal groups using a randomized double AB blocking method based on a random number table.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Tehran University of Medical Sciences

Street address

Keshavarz Blvd- Qods , TUMS

City

Tehran

Province

Tehran

Postal code

1417653911

Approval date

2020-03-19, 1398/12/29

Ethics committee reference number

IR.TUMS.VCR.REC.1399.009

Health conditions studied**1****Description of health condition studied**

Acute Respiratory Distress Syndrome of COVID-19

ICD-10 code

U07.1

ICD-10 code description

COVID-19

Primary outcomes**1****Description**

Adverse events assesment

Timepoint

At the same time of each intervention, 24 hours after each intervention, on days 6, 7, 14 and 28 after the first intervention

Method of measurement

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

2**Description**

Blood oxygen saturation

Timepoint

At Baseline, simultaneously with each intervention and on days 5, 6, 7, 14 after the first intervention

Method of measurement

Evaluation of Pneumonia Improvement

Secondary outcomes**1****Description**

Biomarkers concentrations in plasma

Timepoint

At baseline, 7, 14, 28 days after the first intervention

Method of measurement

Biochemical examination

2**Description**

Respiratory efficacy

Timepoint

From baseline to day 7

Method of measurement

Evaluated by the increase in PaO₂/FiO₂ ratio

3**Description**

Intensive care unit-free days

Timepoint

Up to day 8

Method of measurement

Number of day

4**Description**

Change in clinical symptoms

Timepoint

At Baseline, simultaneously with each intervention and on days 5, 6, 7, 14 after the first intervention

Method of measurement

Evaluation of Pneumonia Improvement

Intervention groups**1****Description**

Intervention group: Intervention group: The intervention group 1, Patients will receive three doses of MSCs. Two doses of 100×10⁶ (±10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2 and day 4.

Category

Treatment - Other

2**Description**

Control group: Patients will receive conventional therapy

Category

Treatment - Other

Recruitment centers**1****Recruitment center****Name of recruitment center**

Shariati Hospital

Full name of responsible person

Mohammad Alian Nejad

Street address

Shariati Hospital., Jalal-e-Al-e-Ahmad Hwy

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8490 1000

Email

Shariatihosp@tums.ac.ir

2**Recruitment center****Name of recruitment center**

Masih Daneshvari Hospital

Full name of responsible person

Mohammad Reza Hashemian

Street address

Masih Daneshvari Hospital., Darabad Avenue., Shahid Bahonar Avenue

City

Tehran

Province

Tehran

Postal code

1956944413

Phone

+98 21 2610 5050

Email

smrhashemian@sbmu.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Execution of Imam Khomeini's Order

Full name of responsible person

Mohammad Mokhber

Street address

Khaled Eslambuli Ave., 17 alley

City

Tehran

Province

Tehran

Postal code

1411533123

Phone

+98 21 8872 5923

Email

info@setad.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Execution of Imam Khomeini's Order

Proportion provided by this source

40
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

2

Sponsor
Name of organization / entity
National Institute for Medical Research Development
Full name of responsible person
Reza Malekzadeh
Street address
No 21, Besat Street., Western Fatimid Street
City
Tehran
Province
Tehran
Postal code
۱۴۱۹۶۹۳۱۱۱
Phone
+98 21 6693 8037
Email
dr.reza.malekzadeh@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
National Institute for Medical Research Development
Proportion provided by this source
20
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

3

Sponsor
Name of organization / entity
Oghaf Organization and charity
Full name of responsible person
Sayed Mahdi Khamooshi
Street address
Nofel Loshato St
City
Tehran
Province
Tehran
Postal code

۱۱۴۱۱۵۳۳۱۶
Phone
+98 21 6897 0000
Email
info@oghaf.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Oghaf Organization and charity
Proportion provided by this source
40
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Other

4

Sponsor
Name of organization / entity
Opal Parsian Company
Full name of responsible person
Mohamad Azimi
Street address
No. 12, 29 Ave, Alvand st.,
City
Tehran
Province
Tehran
Postal code
۱۴۱۱۵۳۳۱۱۲
Phone
+98 21 8608 4871
Email
info@amencapital.co
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Opal Parsian Company
Proportion provided by this source
40
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tarbiat Modares University

Full name of responsible person

Masoud Soleimani

Position

professor

Latest degree

Ph.D.

Other areas of specialty/work

Hematology

Street address

Jalal - al- Ahmad-Chamran High way

City

Tehran

Province

Tehran

Postal code

1415533122

Phone

+98 21 8288 0000

Email

soleim_m@modares.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mohammad Vasei

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pathology

Street address

Shariati Hospital

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8490 1000

Email

mvasei@tums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tarbiat Modares University

Full name of responsible person

Masoud Soleimani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Hematology

Street address

Jalal- al- Ahmad - Chamran highway

City

Tehran

Province

Tehran

Postal code

۱۴۱۵۵۳۳۱۲۲

Phone

+98 21 8288 0000

Email

soleim_m@modares.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

All collected deidentified IPD can be shared

When the data will become available and for how long

6 months after publication

To whom data/document is available

Researchers and clinicians

Under which criteria data/document could be used

Planning of similar studies in other academic centers

From where data/document is obtainable

e-Mail

What processes are involved for a request to access data/document

1-2 months after request

Comments